# VivoSim Labs, INC. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/VivoSim Labs, INC.). ## Overview VivoSim Labs, Inc. is a U.S.-based pharmaceutical and biotechnology services company focused on 3D human tissue models of liver and intestine. Through its subsidiaries, it combines toxicology testing, drug-response research, and related intellectual property licensing around non-animal new approach methodologies (NAMs). ## Products & services • 3D human liver tissue toxicology testing • 3D human intestinal tissue toxicology testing • Investigational toxicology services • Mechanism-of-action elucidation studies • Licensing of intellectual property • Human cell-based research products - **3D tissue toxicology services** (55%) — Testing of drugs and drug candidates in liver and intestinal human tissue models. - **Investigational and mechanism studies** (20%) — Custom research services using complex human tissue models to study drug effects and biology. - **IP licensing and royalties** (20%) — Royalties and licensing income from intellectual property and related agreements. - **Human cell products** (5%) — Cell-based products sold through the former Mosaic Cell Sciences business. - 3D human liver tissue toxicology testing - 3D human intestinal tissue toxicology testing - Investigational toxicology services - Mechanism-of-action elucidation studies - Licensing of intellectual property - Human cell-based research products ## Customers Customers are primarily pharmaceutical and biotechnology companies that need human-relevant data to evaluate drug safety, toxicity, and mechanism of action. The company also serves research collaborators and other life-science customers that use cell-based products or license its intellectual property. - **Pharmaceutical companies** (primary) — Buy toxicology and mechanism studies to de-risk drug candidates before clinical development. - **Biotechnology companies** (primary) — Use 3D tissue models and custom studies to support discovery and translational research. - **Research collaborators** (secondary) — Partner on exploratory studies, validation work, and disease-model applications. - **Life-science product customers** (secondary) — Purchase human cell-based products for R&D and laboratory use. - **Licensees and royalty payors** (secondary) — Generate royalty revenue through use of licensed intellectual property. - Pharma companies testing drug candidates for liver and gut toxicity - Biotech firms seeking human tissue data for lead optimization - Research collaborators needing bespoke toxicology studies - Life-science customers buying cell-based research products - Licensees and partners paying for access to IP and know-how ## Geography VivoSim Labs is headquartered in San Diego, California and operates as a U.S.-based company. The business is organized around domestic scientific, operational, and corporate activities, while customer and licensing relationships may extend beyond the United States depending on partner location. - Headquartered in San Diego, California - U.S.-based corporate and scientific operations - Nasdaq Capital Market listing in the United States - Customer and licensing relationships may be international - Human cell sourcing depends on third-party suppliers ## Strategy The company is repositioning around 3D human tissue models, NAM-based toxicology services, and related intellectual property rather than internal clinical drug development. Its strategy depends on building partner relationships, expanding scientific use cases, and monetizing existing tissue-model assets and IP. - **Grow NAM-based toxicology services** (short-term) — Human tissue models can provide more relevant drug-safety insights than traditional approaches. - **Deepen partner and collaboration network** (medium-term) — External relationships are needed to commercialize services and broaden scientific applications. - **Monetize intellectual property and legacy assets** (medium-term) — Licensing and royalties can support the business while the services platform scales. - Expand adoption of 3D human tissue NAM models - Monetize liver and intestine toxicology expertise - Pursue bespoke scientific services for partners - Use IP licensing and royalties as a recurring revenue stream - Build strategic collaborations with pharma and biotech ## Risks The business depends on unproven commercial adoption of 3D tissue models, continued access to human cells, and the ability to win scientific partners in a competitive market. It also faces financing and execution risk because the services platform and research programs require ongoing capital, specialized personnel, and regulatory acceptance of NAM methods. - **Unproven adoption of 3D tissue models** [high] — Commercial demand may develop slowly if customers do not adopt NAM methods at scale. - **Human cell supply constraints** [high] — The company relies on third-party suppliers for qualified human cells used in tissue models. - **Partnering and collaboration risk** [medium] — The business model depends on strategic relationships to commercialize services and IP. - **Talent retention and recruitment** [medium] — Scientific and operational execution depends on specialized employees and contractors. - **Financing and liquidity pressure** [high] — The company requires additional capital to fund operations and development activities. - 3D tissue models are new and not yet broadly proven commercially - Human cell supply disruptions could limit services and research output - Competition for scientific talent is intense in biotech - Partnering and licensing execution is needed to sustain the model - Ongoing funding needs create going-concern and dilution risk ## Accounting Revenue recognition is important because the company earns a mix of point-in-time product revenue, sales-based royalty revenue, and service revenue tied to contract performance. Stock-based compensation and revenue judgments are key estimates, while the sale of the FXR program and any contingent milestones can affect timing and classification of proceeds. - **Revenue recognition** — Affects timing and volatility of reported revenue - **Sales-based royalties** — Can create lumpy revenue recognition - **Stock-based compensation** — Affects operating expense and reported losses - **Contingent milestone consideration** — Could affect future cash receipts and accounting judgments - Royalty revenue depends on sales-based royalty recognition timing - Service revenue depends on contract performance obligations - Product revenue is recognized when control transfers on delivery - Stock-based compensation relies on forfeiture and valuation estimates - Milestone consideration from FXR sale may affect future revenue --- *Last updated: 2026-04-29T05:08:33.656897+00:00*